Evidence mapPaperPMID 34443613Full record

ArticleMolecules (Basel, Switzerland)2021

3,5-Dicaffeoylquinic Acid Lowers 3T3-L1 Mitotic Clonal Expansion and Adipocyte Differentiation by Enhancing Heme Oxygenase-1 Expression.

Alice Raineri, Rachele Campagnari, Roberto Dal Toso, Stefano Copetti, Macarena Gomez-Lira, Marta Menegazzi

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Anti-Obesity Activity of GiantInternational journal of molecular sciences · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Antioxidants (Basel, Switzerland) · 2023
    Article
  6. Article
  7. Article
  8. Callus Culture ofMolecules (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Alice RaineriDepartment of Neurosciences, Biomedicine and Movement Sciences, School of Medicine, University of Verona, Strada Le Grazie, 8, 37134 Verona, Italy.
Rachele CampagnariDepartment of Neurosciences, Biomedicine and Movement Sciences, School of Medicine, University of Verona, Strada Le Grazie, 8, 37134 Verona, Italy.
Roberto Dal TosoCroda Italiana S.p.A., Via Pietro Grocco, 27036 Mortara, Italy.
Stefano CopettiCroda Italiana S.p.A., Via Pietro Grocco, 27036 Mortara, Italy.
Macarena Gomez-LiraDepartment of Neurosciences, Biomedicine and Movement Sciences, School of Medicine, University of Verona, Strada Le Grazie, 8, 37134 Verona, Italy.
Marta MenegazziDepartment of Neurosciences, Biomedicine and Movement Sciences, School of Medicine, University of Verona, Strada Le Grazie, 8, 37134 Verona, Italy.ORCID 0000-0003-1310-9227
University of Verona · IT

Funding

Università degli Studi di Verona JPVR16YZ3R
6 · The paper itself

Abstract

Adipogenesis is a complex process in which cell commitment and mitotic clonal expansion (MCE) are in-sequence crucial events leading to terminal adipocyte differentiation. The molecules able to block some key signals in this cascade can hamper adipogenesis becoming promising agents to counteract hyperplasia and hypertrophy of adipose tissue. Mono- and di-caffeoylquinic acid isomers are biologically active polyphenols, displaying in vitro and in vivo antioxidant, hepatoprotective, anti-diabetic and anti-obesity properties. Among these isomers, 3,5-dicaffeoylquinic acid (DCQA) has been reported to inhibit lipid accumulation in adipose cells more successfully than others. Thus, we investigated DCQA effects and molecular mechanisms on 3T3-L1 pre-adipocytes induced to differentiate with a hormonal cocktail (MDI). Oil Red O incorporation assessed that DCQA pre-treatment inhibited lipid accumulation in 3T3-L1 cells induced to differentiate for 10 days. At this time, an increased phosphorylation of both AMP-activated kinase and acetyl-CoA carboxylase, as well as a strong decrease in fatty acid synthase protein level, were registered by immunoblotting, thereby suggesting that DCQA treatment can reduce fatty acid anabolism in 3T3-L1 adipocytes. Furthermore, BrdU incorporation assay, performed 48 h after hormonal stimulation, revealed that DCQA treatment was also able to hinder the 3T3-L1 cell proliferation during the MCE, which is an essential step in the adipogenic process. Thus, we focused our attention on early signals triggered by the differentiation stimuli. In the first hours after hormonal cocktail administration, the activation of ERK1/2 and Akt kinases, or CREB and STAT3 transcription factors, was not affected by DCQA pre-treatment. Whereas 24 h after MDI induction, DCQA pre-treated cells showed increased level of the transcription factor Nrf2, that induced the expression of the antioxidant enzyme heme oxygenase 1 (HO-1). In control samples, the expression level of HO-1 was reduced 24 h after MDI induction in comparison with the higher amount of HO-1 protein found at 2 h. The HO-1 decrease was functional by allowing reactive oxygen species to boost and allowing cell proliferation induction at the beginning of MCE phase. Instead, in DCQA-treated cells the HO-1 expression was maintained at high levels for a further 24 h; in fact, its expression decreased only 48 h after MDI stimulation. The longer period in which HO-1 expression remained high led to a delay of the MCE phase, with a subsequent inhibition of both C/EBP-α expression and adipocyte terminal differentiation. In conclusion, DCQA counteracting an excessive adipose tissue expansion may become an attractive option in obesity treatment.

Indexed as

3T3-L1 CellsAdipocytesAdipogenesisCell DifferentiationHeme Oxygenase-1Quinic AcidAnimalsCell ProliferationChlorogenic AcidGene Expression RegulationLipid MetabolismMiceMitosiscaffeoylquinic acidChlorogenic AcidHeme Oxygenase-1Quinic AcidadipogenesisAktAMPKHO-1mitotic clonal expansionnatural productsNrf2

Identifiers

PMID34443613
PMCPMC8402220
OpenAlexW3193496856

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.